Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High – Still a Buy?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hit a new 52-week high during trading on Wednesday . The company traded as high as $26.42 and last traded at $26.3160, with a volume of 9750265 shares trading hands. The stock had previously closed at $24.99.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, UBS Group raised their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $25.86.

Teva Pharmaceutical Industries Price Performance

The firm’s 50 day moving average is $21.12 and its 200 day moving average is $18.63. The firm has a market cap of $30.21 billion, a P/E ratio of -164.53, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $4.48 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares in the company, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its position in Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares in the last quarter. Phoenix Financial Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after buying an additional 9,094,372 shares during the period. Soundwatch Capital LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $143,533,000. Finally, Wellington Management Group LLP increased its holdings in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.